212 related articles for article (PubMed ID: 33846541)
1. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Montalban-Bravo G; Hammond D; DiNardo CD; Konopleva M; Borthakur G; Short NJ; Ramos-Perez J; Guerra V; Kanagal-Shamanna R; Naqvi K; Sasaki K; Jabbour E; Pemmaraju N; Kadia TM; Ravandi F; Daver N; Estrov Z; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2021 May; 35(5):1494-1499. PubMed ID: 33846541
[No Abstract] [Full Text] [Related]
2. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.
Saliba AN; Litzow MR; Gangat N; Al-Kali A; Foran JM; Hogan WJ; Palmer JM; Mangaonkar AA; Tefferi A; Patnaik MM
Am J Hematol; 2021 Nov; 96(11):E433-E436. PubMed ID: 34428328
[No Abstract] [Full Text] [Related]
3. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
[No Abstract] [Full Text] [Related]
4. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
6. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
[No Abstract] [Full Text] [Related]
7. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
8. Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Assouline S
Lancet Haematol; 2024 Mar; 11(3):e170-e171. PubMed ID: 38316134
[No Abstract] [Full Text] [Related]
9. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
10. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A; Mauro FR; Scarfò L; Gentile M; Farina L; Reda G; Ferrarini I; Proietti G; Derenzini E; Cibien F; Vitale C; Sanna A; Pietrasanta D; Marchetti M; Murru R; Rigolin GM; Sportoletti P; Trimarco V; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Zatta I; Laurenti L; Molica S; Coscia M; Ghia P; Foà R; Cuneo A; Trentin L
Am J Hematol; 2023 Sep; 98(9):E237-E240. PubMed ID: 37382471
[No Abstract] [Full Text] [Related]
11. Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
Benedetti E; Baratè C; Bruno B; Bramanti E; Ghia P; Scarfò L; Morganti R; Ricchiuto V; Galimberti S
Leuk Res; 2021 Jan; 100():106488. PubMed ID: 33316660
[No Abstract] [Full Text] [Related]
12. Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
Innocenti I; Morelli F; Autore F; Tomasso A; Corbingi A; Bellesi S; Za T; De Stefano V; Laurenti L
Leuk Lymphoma; 2019 Dec; 60(12):3078-3080. PubMed ID: 31106622
[No Abstract] [Full Text] [Related]
13. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
14. Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
Blood; 2023 Mar; 141(11):1366. PubMed ID: 36929430
[No Abstract] [Full Text] [Related]
15. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.
Reda G; Cassin R; Dovrtelova G; Matteo C; Giannotta J; D'Incalci M; Cortelezzi A; Zucchetti M
Haematologica; 2019 May; 104(5):e222-e223. PubMed ID: 30765472
[No Abstract] [Full Text] [Related]
16. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
17. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
[TBL] [Abstract][Full Text] [Related]
18. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
Zou HS; Yi SH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
[No Abstract] [Full Text] [Related]
19. Venetoclax Data Prompt Rethink of CLL Therapy.
Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Ball S; Jain AG; Aguirre LE; Al Ali N; Zhang Y; Chan O; Kuykendall AT; Sweet KL; Lancet JE; Swoboda DM; Padron E; Komrokji RS; Sallman DA
Am J Hematol; 2022 May; 97(5):E185-E188. PubMed ID: 35179241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
